知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.017 秒)

    Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
    1.
    发明授权
    Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors 有权
    组蛋白脱乙酰酶抑制剂和Her2抑制剂或PI3K抑制剂的组合

    公开(公告)号：US09403779B2

    公开(公告)日：2016-08-02

    申请号：US14506889

    申请日：2014-10-06

    申请人： ACETYLON PHARMACEUTICALS, INC.

    发明人： David Lee Tamang ,  Min Yang ,  Simon S. Jones

    IPC分类号： A61K31/505 ,  C07D239/42 ,  A61K31/517 ,  A61K31/5377

    CPC分类号： A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D239/42 ,  A61K2300/00

    摘要： The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatment of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.

    摘要翻译： 本发明涉及包含HDAC抑制剂和Her2抑制剂的组合物，用于在有需要的受试者中治疗乳腺癌。 本发明还涉及包含HDAC抑制剂和PI3K抑制剂的组合，用于在有需要的受试者中治疗乳腺癌。 本文还提供了在有需要的受试者中治疗乳腺癌的方法，其包括向受试者施用有效量的上述组合之一。 还提供了通过向受试者施用HDAC6特异性抑制剂来抑制受试者中乳腺癌细胞迁移和/或侵袭的方法。

    HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA
    3.
    发明申请
    HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA 审中-公开
    HISTONE DEACETYLASE（HDAC）生物标志物在多种MYELOMA

    公开(公告)号：US20140357512A1

    公开(公告)日：2014-12-04

    申请号：US14294833

    申请日：2014-06-03

    申请人： ACETYLON PHARMACEUTICALS, INC.

    发明人： Min Yang ,  Simon S. Jones

    IPC分类号： G01N33/574 ,  G01N33/50

    CPC分类号： G01N33/57407 ,  C12N9/16 ,  G01N33/5011 ,  G01N33/57426 ,  G01N33/57496 ,  G01N2333/98 ,  G01N2440/10 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2800/52

    摘要： The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

    摘要翻译： 本发明涉及多发性骨髓瘤中的组蛋白脱乙酰酶（HDAC）生物标志物。 具体地，生物标志物是药物特异性的，用于多发性骨髓瘤的乙酰化的组蛋白脱乙酰酶（HDAC）或HDAC6生物标记肽。 或者，生物标志物是用于多发性骨髓瘤的药物特异性的HDAC6生物标记肽，其被乙酰化或未乙酰化。 本发明还涉及包含检测剂的试剂盒和用于鉴定本发明的生物标志物肽的说明书。 本发明还涉及用于监测受试者中HDAC抑制剂的治疗效率的方法。

    TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS
    4.
    发明申请
    TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS 有权
    用HISTONE脱乙酰壳多糖酶抑制剂处理低密度脂蛋白

    公开(公告)号：US20160030458A1

    公开(公告)日：2016-02-04

    申请号：US14792046

    申请日：2015-07-06

    申请人： Acetylon Pharmaceuticals Inc.

    发明人： Simon S. Jones ,  Chengyin Min ,  Min Yang ,  David Lee Tamang

    IPC分类号： A61K31/706 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/505

    CPC分类号： A61K31/706 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.

    摘要翻译： 本文提供了包含HDAC抑制剂和阿扎胞苷的组合，用于在有需要的受试者中治疗白血病。 本文提供了包含HDAC抑制剂和阿扎胞苷的组合，用于在有需要的受试者中治疗急性骨髓性白血病。 本文还提供了在有需要的受试者中治疗白血病的方法，包括给予受试者有效量的上述组合或HDAC抑制剂，以及在有需要的受试者中治疗急性骨髓性白血病的方法，包括施用 对该受试者有效量的上述组合或HDAC抑制剂。

    COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS
    6.
    发明申请
    COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS 审中-公开
    组合脱乙酰壳多糖酶抑制剂和HER2抑制剂或PI3K抑制剂的组合

    公开(公告)号：US20170020872A1

    公开(公告)日：2017-01-26

    申请号：US15189554

    申请日：2016-06-22

    申请人： Acetylon Pharmaceuticals, Inc.

    发明人： David Lee Tamang ,  Min Yang ,  Simon S. Jones

    IPC分类号： A61K31/505 ,  A61K45/06

    摘要： The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatment of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.

    摘要翻译： 本发明涉及包含HDAC抑制剂和Her2抑制剂的组合物，用于在有需要的受试者中治疗乳腺癌。 本发明还涉及包含HDAC抑制剂和PI3K抑制剂的组合，用于在有需要的受试者中治疗乳腺癌。 本文还提供了在有需要的受试者中治疗乳腺癌的方法，其包括向受试者施用有效量的上述组合之一。 还提供了通过向受试者施用HDAC6特异性抑制剂来抑制受试者中乳腺癌细胞迁移和/或侵袭的方法。

    TREATMENT OF NEUROBLASTOMA WITH HISTONE DEACETYLASE INHIBITORS
    9.
    发明申请
    TREATMENT OF NEUROBLASTOMA WITH HISTONE DEACETYLASE INHIBITORS 审中-公开
    用脱乙酰壳多糖酶抑制剂治疗神经生长因子

    公开(公告)号：US20160339022A1

    公开(公告)日：2016-11-24

    申请号：US15130351

    申请日：2016-04-15

    申请人： Acetylon Pharmaceuticals Inc.

    发明人： David Lee Tamang ,  Simon S. Jones ,  Min Yang

    IPC分类号： A61K31/505 ,  A61K31/496 ,  A61K31/5377

    CPC分类号： A61K31/505 ,  A61K31/203 ,  A61K31/496 ,  A61K31/5377 ,  A61K2300/00

    摘要： Provided herein are combinations comprising an HDAC inhibitor and retinoic acid for the treatment of neuroblastoma in a subject in need thereof. Also provided herein are methods for treating neuroblastoma in a subject in need thereof, comprising administering to the subject an effective amount of the above HDAC inhibitor or combination, comprising administering to the subject in need thereof an effective amount of the above HDAC inhibitor or combination. Also provided herein is a method for predicting whether a neuroblastoma patient will respond to treatment with a combination comprising an HDAC inhibitor and retinoic acid.

    摘要翻译： 本文提供了包含HDAC抑制剂和视黄酸的组合，用于在有需要的受试者中治疗神经母细胞瘤。 本文还提供了在有需要的受试者中治疗神经母细胞瘤的方法，包括向所述受试者施用有效量的上述HDAC抑制剂或组合，包括向有需要的受试者施用有效量的上述HDAC抑制剂或组合。 本文还提供了一种用于预测神经母细胞瘤患者是否将以包含HDAC抑制剂和视黄酸的组合的治疗反应的方法。